JPWO2020069442A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020069442A5 JPWO2020069442A5 JP2021517865A JP2021517865A JPWO2020069442A5 JP WO2020069442 A5 JPWO2020069442 A5 JP WO2020069442A5 JP 2021517865 A JP2021517865 A JP 2021517865A JP 2021517865 A JP2021517865 A JP 2021517865A JP WO2020069442 A5 JPWO2020069442 A5 JP WO2020069442A5
- Authority
- JP
- Japan
- Prior art keywords
- tertiary
- aminolipidated
- cationic peptide
- pegylated cationic
- peptide compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims 27
- 125000002091 cationic group Chemical group 0.000 claims 24
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 4
- 150000002632 lipids Chemical group 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical group CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001302 tertiary amino group Chemical group 0.000 claims 1
Claims (28)
- sが3又は4である、請求項1に記載の第三級アミノ脂質化及び/又はPEG化カチオン性ペプチド化合物。
- 各R3が、独立して、C 8 -C 12 -アルキルである、請求項1又は2に記載の第三級アミノ脂質化及び/又はPEG化カチオン性ペプチド化合物。
- Ra及びRbが、-Hである、請求項1から5のいずれか一項に記載の第三級アミノ脂質化及び/又はPEG化カチオン性ペプチド化合物。
- ポリアニオン性化合物と複合体を形成した、請求項1から6のいずれか一項に記載の第三級アミノ脂質化及び/又はPEG化カチオン性ペプチド化合物の1つ又は複数を含む複合体。
- ポリアニオン性化合物が核酸を含む、請求項7に記載の複合体。
- ポリアニオン性化合物がポリペプチドをコードするmRNAを含む、請求項7又は請求項8に記載の複合体。
- ポリアニオン性化合物が核酸を含み、複合体が、少なくとも1つの第三級アミノ脂質化及び/又はPEG化カチオン性ペプチドと、核酸とを、0.5:1から50:1の間の質量比で含む、請求項7から9のいずれか一項に記載の複合体。
- 複合体が、1つ又は複数の第三級アミノ脂質化及び/又はPEG化カチオン性ペプチド化合物、核酸、リン脂質、任意選択で構造脂質、及びPEG脂質を含む、請求項7から10のいずれか一項に記載の複合体。
- 細胞を、請求項7から11のいずれか一項に記載の複合体と接触させることを含む、ポリアニオン性化合物を細胞に送達する方法。
- ポリアニオン性化合物が、ポリペプチドをコードするmRNAを含み、細胞が複合体と接触した後に該ポリペプチドを発現する、請求項12に記載の方法。
- 第三級アミノ脂質化及び/又はPEG化カチオン性ペプチド化合物を、ポリアニオン性化合物と接触させることを含む、請求項7から11のいずれか一項に記載の方法。
- R 7 が、-NH 2 である、請求項1に記載の第三級アミノ脂質化及び/又はPEG化カチ性ペプチド化合物。
- R 5 が、ヒドロキシアルキル又はヒドロキシエーテルである、請求項1に記載の第三級アミノ脂質化及び/又はPEG化カチオン性ペプチド化合物。
- R 5 が、ヒドロキシアルキルである、請求項17に記載の第三級アミノ脂質化及び/又はPEG化カチオン性ペプチド化合物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862738717P | 2018-09-28 | 2018-09-28 | |
US62/738,717 | 2018-09-28 | ||
US201962885036P | 2019-08-09 | 2019-08-09 | |
US62/885,036 | 2019-08-09 | ||
PCT/US2019/053655 WO2020069442A1 (en) | 2018-09-28 | 2019-09-27 | Tertiary amino lipidated cationic peptides for nucleic acid delivery |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2022501408A JP2022501408A (ja) | 2022-01-06 |
JPWO2020069442A5 true JPWO2020069442A5 (ja) | 2022-10-05 |
JP7418419B2 JP7418419B2 (ja) | 2024-01-19 |
Family
ID=69952323
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021517802A Active JP7430713B2 (ja) | 2018-09-28 | 2019-09-27 | 核酸送達のための脂質化カチオン性ペプチド化合物を含む脂質ナノ粒子製剤 |
JP2021517865A Active JP7418419B2 (ja) | 2018-09-28 | 2019-09-27 | 核酸送達のための第三級アミノ脂質化カチオン性ペプチド |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021517802A Active JP7430713B2 (ja) | 2018-09-28 | 2019-09-27 | 核酸送達のための脂質化カチオン性ペプチド化合物を含む脂質ナノ粒子製剤 |
Country Status (13)
Country | Link |
---|---|
US (4) | US20210324002A1 (ja) |
EP (2) | EP3856146A4 (ja) |
JP (2) | JP7430713B2 (ja) |
KR (2) | KR20210068093A (ja) |
CN (2) | CN112789031B (ja) |
AU (2) | AU2019351268A1 (ja) |
BR (2) | BR112021005815A2 (ja) |
CA (2) | CA3111476A1 (ja) |
IL (2) | IL281135A (ja) |
MX (2) | MX2021003420A (ja) |
SG (2) | SG11202102164PA (ja) |
WO (2) | WO2020069442A1 (ja) |
ZA (1) | ZA202101465B (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210068093A (ko) * | 2018-09-28 | 2021-06-08 | 넛크래커 테라퓨틱스 인코포레이티드 | 핵산 전달을 위한 지질화 양이온성 펩타이드 화합물을 포함하는 지질 나노입자 제형 |
TW202220674A (zh) | 2020-08-07 | 2022-06-01 | 美商胡桃夾子治療公司 | 用於聚陰離子貨物化合物遞送的多組分遞送系統 |
NL2026825B1 (en) | 2020-08-07 | 2022-04-05 | Nutcracker Therapeutics Inc | Multicomponent delivery system for polyanionic cargo compound delivery |
AU2022271263A1 (en) * | 2021-05-05 | 2023-11-16 | Arcturus Therapeutics, Inc. | Peptide-lipid conjugates |
NL2029057B1 (en) | 2021-08-06 | 2023-02-21 | Nutcracker Therapeutics Inc | Compositions comprising hydroxyethyl-capped cationic peptoids |
WO2023014931A1 (en) | 2021-08-06 | 2023-02-09 | Nutcracker Therapeutics, Inc. | Compositions comprising hydroxyethyl-capped cationic peptoids |
CN114778712B (zh) * | 2022-03-21 | 2023-06-02 | 天津键凯科技有限公司 | 一种聚乙二醇脂质及含有该脂质的脂质纳米粒含量的检测方法 |
WO2024054617A1 (en) | 2022-09-09 | 2024-03-14 | Nutcracker Therapeutics, Inc. | 2-aminopropane-1,3-diol-capped cationic peptoids for nucleic acid delivery |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
JP4656675B2 (ja) | 1997-05-14 | 2011-03-23 | ユニバーシティー オブ ブリティッシュ コロンビア | 脂質小胞への荷電した治療剤の高率封入 |
US6191115B1 (en) * | 1998-08-12 | 2001-02-20 | Abbott Laboratories | C-terminus modified heptapeptide LHRH analogs |
WO2001016306A2 (en) * | 1999-08-27 | 2001-03-08 | Chiron Corporation | Chimeric antisense oligonucleotides and cell transfecting formulations thereof |
CA2445947A1 (en) * | 2001-04-30 | 2002-11-07 | Targeted Genetics Corporation | Lipid-comprising drug delivery complexes and methods for their production |
ATE485031T1 (de) | 2002-06-28 | 2010-11-15 | Protiva Biotherapeutics Inc | Verfahren und vorrichtung zur herstellung von liposomen |
ES2559828T3 (es) * | 2003-07-16 | 2016-02-16 | Protiva Biotherapeutics Inc. | ARN de interferencia encapsulado en lípidos |
CA2549720C (en) * | 2003-12-19 | 2013-10-15 | Chiron Corporation | Cell transfecting formulations of small interfering rna, related compositions and methods of making and use |
ITMI20061607A1 (it) * | 2006-08-09 | 2008-02-10 | Maria Vincenza Carriero | Peptidi con attivita farmacologica |
CN101820966B (zh) | 2007-06-04 | 2017-10-27 | 高压生物科学公司 | 分子的压力提高的提取和分配 |
DK2279254T3 (en) | 2008-04-15 | 2017-09-18 | Protiva Biotherapeutics Inc | PRESENT UNKNOWN LIPID FORMS FOR NUCLEIC ACID ADMINISTRATION |
EP2355851B1 (en) | 2008-11-10 | 2018-04-04 | Arbutus Biopharma Corporation | Novel lipids and compositions for the delivery of therapeutics |
CA2742689A1 (en) * | 2008-11-17 | 2010-05-20 | Enzon Pharmaceuticals, Inc. | Branched cationic lipids for nucleic acids delivery system |
ES2613498T3 (es) | 2009-07-01 | 2017-05-24 | Protiva Biotherapeutics Inc. | Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos |
US20110053829A1 (en) * | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
CN102712935B (zh) | 2009-11-04 | 2017-04-26 | 不列颠哥伦比亚大学 | 含有核酸的脂质粒子及相关的方法 |
DK3338765T3 (en) | 2009-12-01 | 2019-03-04 | Translate Bio Inc | STEROID DERIVATIVE FOR THE SUPPLY OF MRNA IN HUMANGENETIC DISEASES |
WO2011153120A1 (en) | 2010-06-04 | 2011-12-08 | Merck Sharp & Dohme Corp. | Novel low molecular weight cationic lipids for oligonucleotide delivery |
US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
CA2818662C (en) | 2010-10-22 | 2021-07-06 | Sungkyunkwan University Foundation For Corporate Collaboration | Nucleic acid molecule inducing rna interference, and uses thereof |
CA2832073A1 (en) * | 2011-04-12 | 2012-10-18 | Terrence R. Burke | Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use |
PL2717893T3 (pl) | 2011-06-08 | 2019-12-31 | Translate Bio, Inc. | Kompozycje nanocząstek lipidowych i sposoby do dostarczania mRNA |
US9579338B2 (en) | 2011-11-04 | 2017-02-28 | Nitto Denko Corporation | Method of producing lipid nanoparticles for drug delivery |
US9035039B2 (en) | 2011-12-22 | 2015-05-19 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing SMAD4 |
US9446132B2 (en) | 2012-03-27 | 2016-09-20 | Sima Therapeutics, Inc. | Diether based biodegradable cationic lipids for siRNA delivery |
ES2836279T3 (es) | 2012-04-04 | 2021-06-24 | Samyang Biopharmaceuticals | Método de preparación de una composición para administrar un fármaco aniónico |
WO2013185069A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Pulmonary delivery of mrna to non-lung target cells |
WO2013192310A1 (en) | 2012-06-19 | 2013-12-27 | Massachusetts Institute Of Technology | Mass production and size control of nanoparticles through controlled microvortices |
TW201408625A (zh) | 2012-07-06 | 2014-03-01 | Kyowa Hakko Kirin Co Ltd | 陽離子性脂質 |
WO2014089239A1 (en) | 2012-12-07 | 2014-06-12 | Alnylam Pharmaceuticals, Inc. | Improved nucleic acid lipid particle formulations |
ES2797974T3 (es) | 2013-03-14 | 2020-12-04 | Translate Bio Inc | Acidos ribonucleicos con nucleótidos modificados con 4-tio y procedimientos relacionados |
ES2702466T3 (es) | 2013-08-21 | 2019-03-01 | Curevac Ag | Procedimiento para aumentar la expresión de proteínas codificadas por ARN |
PT3134131T (pt) | 2014-04-23 | 2022-03-24 | Modernatx Inc | Vacinas de ácidos nucleicos |
CA2951707A1 (en) | 2014-06-10 | 2015-12-17 | Massachusetts Institute Of Technology | Method for gene editing |
ES2555160B1 (es) | 2014-06-24 | 2016-10-25 | Aptus Biotech, S.L. | Aptámeros específicos de TLR-4 y usos de los mismos |
JP7105065B2 (ja) | 2014-12-15 | 2022-07-22 | ダイセルナ ファーマシューティカルズ, インコーポレイテッド | リガンド修飾二本鎖核酸 |
CN113679689B (zh) | 2015-07-22 | 2023-09-01 | 日东电工株式会社 | 用于纳米粒冷冻干燥物形式的组合物及方法 |
MD3718565T2 (ro) | 2015-10-22 | 2022-09-30 | Modernatx Inc | Vaccinuri împotriva virusului respirator |
EP3386519B1 (en) | 2015-12-13 | 2021-03-24 | Nitto Denko Corporation | Sirna structures for high activity and reduced off target |
EP3519578B1 (en) * | 2016-10-03 | 2021-12-22 | Precision Nanosystems Inc | Compositions for transfecting resistant cell types |
CA3043033A1 (en) | 2016-11-10 | 2018-05-17 | Translate Bio, Inc. | Improved ice-based lipid nanoparticle formulation for delivery of mrna |
US20200069594A1 (en) | 2016-12-09 | 2020-03-05 | Board Of Regents, The University Of Texas System | Hybrid exosomal-polymeric (hexpo) nano-platform for delivery of rnai therapeutics |
EP3642341A4 (en) | 2017-06-23 | 2021-06-16 | University Of Massachusetts | TWO-DAY SELF-RELEASING SIRNA AND RELATED PROCEDURES |
KR20210068093A (ko) * | 2018-09-28 | 2021-06-08 | 넛크래커 테라퓨틱스 인코포레이티드 | 핵산 전달을 위한 지질화 양이온성 펩타이드 화합물을 포함하는 지질 나노입자 제형 |
-
2019
- 2019-09-27 KR KR1020217012769A patent/KR20210068093A/ko active Search and Examination
- 2019-09-27 US US17/279,508 patent/US20210324002A1/en active Pending
- 2019-09-27 CN CN201980062278.2A patent/CN112789031B/zh active Active
- 2019-09-27 EP EP19864088.0A patent/EP3856146A4/en active Pending
- 2019-09-27 MX MX2021003420A patent/MX2021003420A/es unknown
- 2019-09-27 AU AU2019351268A patent/AU2019351268A1/en active Pending
- 2019-09-27 SG SG11202102164PA patent/SG11202102164PA/en unknown
- 2019-09-27 BR BR112021005815-0A patent/BR112021005815A2/pt unknown
- 2019-09-27 SG SG11202102163SA patent/SG11202102163SA/en unknown
- 2019-09-27 JP JP2021517802A patent/JP7430713B2/ja active Active
- 2019-09-27 KR KR1020217012768A patent/KR20210068092A/ko unknown
- 2019-09-27 US US17/279,460 patent/US20210322575A1/en active Pending
- 2019-09-27 BR BR112021004929-0A patent/BR112021004929A2/pt unknown
- 2019-09-27 MX MX2021003421A patent/MX2021003421A/es unknown
- 2019-09-27 WO PCT/US2019/053655 patent/WO2020069442A1/en active Application Filing
- 2019-09-27 CN CN201980062070.0A patent/CN112805294A/zh active Pending
- 2019-09-27 CA CA3111476A patent/CA3111476A1/en active Pending
- 2019-09-27 AU AU2019347774A patent/AU2019347774A1/en active Pending
- 2019-09-27 CA CA3110914A patent/CA3110914A1/en active Pending
- 2019-09-27 JP JP2021517865A patent/JP7418419B2/ja active Active
- 2019-09-27 WO PCT/US2019/053661 patent/WO2020069445A1/en active Application Filing
- 2019-09-27 EP EP19866196.9A patent/EP3856757A4/en active Pending
-
2021
- 2021-02-26 IL IL281135A patent/IL281135A/en unknown
- 2021-03-03 ZA ZA2021/01465A patent/ZA202101465B/en unknown
- 2021-03-19 IL IL281653A patent/IL281653A/en unknown
- 2021-06-14 US US17/347,539 patent/US11446394B2/en active Active
- 2021-06-14 US US17/347,498 patent/US11701434B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021011503A (ja) | 製剤用化合物 | |
CN107208095B (zh) | 用于使乙型肝炎病毒基因表达沉默的组合物和方法 | |
JP7075669B2 (ja) | 核酸送達用カチオン性脂質及びその調製物 | |
JP2017536092A5 (ja) | ||
US20230212578A1 (en) | Compositions and methods for treating hypertriglyceridemia | |
JP5475753B2 (ja) | 核酸送達用の脂質製剤 | |
US7709449B2 (en) | Nucleic acid-based compounds and methods of use thereof | |
US20070218122A1 (en) | siRNA silencing of influenza virus gene expression | |
JP2016525146A5 (ja) | ||
CN110974981A (zh) | 用于递送信使rna的组合物和方法 | |
WO2016071857A1 (en) | Compositions and methods for silencing ebola virus expression | |
JPWO2020069442A5 (ja) | ||
JP2008512097A (ja) | アプタマー医薬品化学 | |
JPWO2020081938A5 (ja) | ||
JPWO2020219941A5 (ja) | ||
US20200297867A1 (en) | Surface functionalization of liposomes and liposomal spherical nucleic acids (snas) | |
CN115461042A (zh) | 制备负载mrna的脂质纳米颗粒的改进方法 | |
TW201919653A (zh) | 用於治療b型肝炎之治療組合物及方法 | |
US20240050463A1 (en) | Therapeutic compositions and methods for treating hepatitis b | |
CN113286622A (zh) | 含硅的阳离子脂质 | |
JP2009542582A5 (ja) | ||
JP2001515060A5 (ja) | ||
JP2008542270A5 (ja) | ||
CN116490166A (zh) | 制备加载mRNA的脂质纳米颗粒的改进方法 | |
AU2020202816A1 (en) | Lipid containing formulations |